MedTrace Logo

CFTR Modulators and Gastrointestinal Complications

NCT05253859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47023

Last updated 2024-07-03

No results posted yet for this study

Summary

To elucidate the similarities and distinctions in non-pulmonary manifestations of cystic fibrosis (CF) including distal intestinal obstruction syndrome (DIOS) incidence and pancreatic enzyme replacement therapy (PERT) use between US and UK CF populations in a parallel study using data from the UK and US CF registries. To assess how CFTR modulators impacted upon recorded PERT use and incidence of DIOS.

Conditions

  • Cystic Fibrosis
  • Gastrointestinal System Disease
  • Distal Intestinal Obstruction Syndrome
  • Pancreatic Enzyme Abnormality
  • Pancreatic Disease
  • Lung Diseases
  • Digestive System Disease

Interventions

OTHER

No intervention

Registry study: No intervention

Sponsors & Collaborators

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • University of Washington

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • Nottingham University Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Alan Smyth · Nottingham University Hospitals NHS Trust

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2024-02-10
Completion
2024-02-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253859 on ClinicalTrials.gov